Sage's sec­ond chance at de­pres­sion hits the PhI­II pri­ma­ry, but ques­tions re­main over dura­bil­i­ty, side ef­fects

Look­ing to make a come­back af­ter a big Phase III flop, Sage Ther­a­peu­tics re­vealed da­ta they be­lieve could change the en­tire de­pres­sion treat­ment land­scape, giv­en …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER